Medicus Pharma Ltd. Warrant SC 13G Medicus Pharma / Hathaway John Jason ownership change

SCHEDULE 13G

CUSIP No.

58471K202

Names of Reporting Persons

John Hathaway

Check the appropriate box if a member of a Group (see instructions)

(a)

(b)

Sec Use Only

Citizenship or Place of Organization

UNITED STATES

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 800,952.00
6	Shared Voting Power 0.00
7	Sole Dispositive Power 800,952.00
8	Shared Dispositive Power 0.00

Aggregate Amount Beneficially Owned by Each Reporting Person

800,952.00

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

Checkbox not checked

Percent of class represented by amount in row (9)

6.8 %

Type of Reporting Person (See Instructions)

Comment for Type of Reporting Person: Consists of 800,952 held by SkinJect Partners LLC, an entity controlled by John Hathaway. John Hathaway may be deemed the beneficial owner of securities held by SkinJect Partners LLC. John Hathaway disclaims beneficial ownership of such securities except to the extent of his direct ownership.

SCHEDULE 13G

CUSIP No.

58471K202

Names of Reporting Persons

SkinJect Partners LLC

Check the appropriate box if a member of a Group (see instructions)

(a)

(b)

Sec Use Only

Citizenship or Place of Organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 800,952.00
6	Shared Voting Power 0.00
7	Sole Dispositive Power 800,952.00
8	Shared Dispositive Power 0.00

Aggregate Amount Beneficially Owned by Each Reporting Person

800,952.00

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

Checkbox not checked

Percent of class represented by amount in row (9)

6.8 %

Type of Reporting Person (See Instructions)

SCHEDULE 13G

Item 1.

(a)

Name of issuer:

Medicus Pharma Ltd.

(b)

Address of issuer's principal executive offices:

300 Conshohocken State Road, Suite 200, W. Conshohocken, PA 19428

Item 2.

(a)

Name of person filing:

This statement is being filed on behalf of each of the following persons (collectively, the "Reporting Persons"): (i) John Hathaway; and (ii) SkinJect Partners LLC.

(b)

Address or principal business office or, if none, residence:

The principal business address of each of the Reporting Persons is as follows: 285 Kappa Drive, Suite 100 Pittsburgh, PA 15238

(c)

Citizenship:

See Row (4) of each Reporting Person's cover page.

(d)

Title of class of securities:

Common shares, no par value

(e)

CUSIP No.:

58471K202

Item 3.

If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:

(a)

Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);

(b)

Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);

(c)

Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);

(d)

Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);

(e)

An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);

(f)

An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);

(g)

A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);

(h)

A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);

(i)

A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);

(j)

A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J),
please specify the type of institution:

(k)

Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).

Item 4.

Ownership

(a)

Amount beneficially owned:

SkinJect Partners LLC, an entity controlled by John Hathaway, directly owns 800,952 common shares of Medicus Pharma Ltd. (the "Company"). John Hathaway may be deemed the beneficial owner of securities held by SkinJect Partners LLC. John Hathaway disclaims beneficial ownership of such securities except to the extent of his direct ownership.

(b)

Percent of class:

See Row (11) of each Reporting Person's cover page. The percentages used herein are calculated based upon on an aggregate of 11,816,721 common shares reported by the Company to be outstanding as of November 22, 2024, as reflected in the Company's Management's Discussion and Analysis filed as Exhibit 99.1 to the Company's Form 6-K filed on November 25, 2024. %

(c)

Number of shares as to which the person has:

(i) Sole power to vote or to direct the vote:

See Row (5) of each Reporting Person's cover page.

(ii) Shared power to vote or to direct the vote:

See Row (6) of each Reporting Person's cover page.

(iii) Sole power to dispose or to direct the disposition of:

See Row (7) of each Reporting Person's cover page.

(iv) Shared power to dispose or to direct the disposition of:

See Row (8) of each Reporting Person's cover page.

Item 5.

Ownership of 5 Percent or Less of a Class.

Item 6.

Ownership of more than 5 Percent on Behalf of Another Person.

Not Applicable

Item 7.

Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.

Not Applicable

Item 8.

Identification and Classification of Members of the Group.

Not Applicable

Item 9.

Notice of Dissolution of Group.

Not Applicable

Item 10.

Certifications:

Not Applicable

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

John Hathaway

Signature:	/s/ John Hathaway
Name/Title:	John Hathaway
Date:	02/10/2025

SkinJect Partners LLC

Signature:	/s/ John Hathaway
Name/Title:	John Hathaway, Managing Director
Date:	02/10/2025

Exhibit Information

Exhibit 99.1: Joint Filing Agreement.

Medicus Pharma Ltd. Warrant (MDCX) SC 13GMedicus Pharma / Hathaway John Jason ownership change